首页 > 市场调查报告书 > 製药

医药品原料药

市场调查报告书

商品编码

1489161

全球赖诺普利市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Lisinopril Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年05月01日 | 出版商:

Value Market Research | 英文 221 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球赖诺普利市场需求预计将从2023年的20.9亿美元达到近33.5亿美元的市场规模，2024-2032年研究期间复合年增长率为5.36%。

赖诺普利被归类为血管紧张素转换酶 (ACE) 抑制剂，主要用于治疗高血压和心臟衰竭。其机制涉及放鬆血管，从而降低血压并改善血流。它也用于提高心臟病发作后的存活率，并治疗与糖尿病相关的某些肾臟疾病。通常，口服，每天一次，可以与食物一起服用，也可以不与食物一起服用。常见的副作用包括头晕、头痛和咳嗽。透过有效管理血压，它有助于降低中风、心臟病和肾臟问题的风险。

市场动态

高血压和心血管疾病的发生率不断增加是一个重要的驱动因素，因为赖诺普利被广泛用于治疗这些疾病。随着全球人口的增长和与生活方式相关的健康问题的增加，对有效抗高血压药物的需求持续上升。此外，该药物经过验证的功效和安全性使其成为医疗保健提供者的首选。发展中地区医疗保健服务范围的不断扩大是另一个重要因素。随着越来越多的人获得医疗服务，高血压的诊断和治疗变得更加普遍，从而促进了市场的成长。此外，人口老化对市场成长做出了重大贡献，因为老年人更容易患高血压和相关心血管疾病。製药公司也投资于行销和宣传活动，以教育患者和医疗保健专业人员了解赖诺普利的好处，这有助于推动其采用。最后，药品製造的进步使得能够以更实惠的价格生产高品质的赖诺普利，从而使更广泛的患者群体能够使用它。然而，仿製药替代品的出现和潜在的副作用可能会挑战未来几年的市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对赖诺普利全球市场的每个细分市场进行了包容性评估。赖诺普利产业的成长和趋势为本研究提供了整体方法。

市场区隔

赖诺普利市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按剂量

药片
液体

按剂量强度

10毫克
20毫克
25毫克

按患者年龄组

孩子们
成年人

按申请

高血压
心臟衰竭
心臟病发作
糖尿病肾病变
其他

按配销通路

医院药房
零售药房
网路药房

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲赖诺普利市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。赖诺普利市场的主要参与者包括艾伯维公司、Amneal Pharmaceutical Inc.、阿斯特捷利康、Apotex Inc.、Aurobindo Pharma Ltd.、Bausch Health Companies Inc.、Cipla Limited、Hikma Pharmaceutical PLC.、Lupin Limited、 Merck & Co. Inc. .、辉瑞公司、Sun Pharmaceutical Industries Limited、Teva Pharmaceutical Industries Limited、Vitaris Inc.、Zydus Lifesciences Limited。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

简介 - 市场动态
市场驱动因素
市场限制
机会
产业动态
波特五力分析
市场吸引力分析
- 按剂量进行的市场吸引力分析
- 按剂量强度进行的市场吸引力分析
- 按患者年龄组别分類的市场吸引力分析
- 市场吸引力分析：依应用分类
- 按配销通路分類的市场吸引力分析
- 市场吸引力分析：按地区

第 4 章：价值链分析

价值链分析
原料分析
- 原料清单
- 原料厂商清单
- 主要原物料价格走势
潜在买家名单
行销管道
- 直效行销
- 间接行销
- 行销通路发展趋势

第 5 章：全球赖诺普利市场分析：按剂量

按剂量概述
按剂量进行历史和预测数据分析
药片
液体

第 6 章：全球赖诺普利市场分析：依剂量强度

按剂量强度概述
按剂量强度进行历史和预测数据分析
10毫克
20毫克
25毫克

第 7 章：全球赖诺普利市场分析：依病患年龄层分类

按患者年龄组别分類的概述
按患者年龄组进行历史和预测数据分析
孩子们
成年人

第 8 章：全球赖诺普利市场分析：依应用分类

概述：按应用
历史和预测数据分析：按应用
高血压
心臟衰竭
心臟病发作
糖尿病肾病变
其他

第 9 章：全球赖诺普利市场分析：按分销管道

配销通路概览
按配销通路进行历史和预测资料分析
医院药房
零售药房
网路药房

第 10 章：全球赖诺普利市场分析：依地理位置

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 11 章：赖诺普利公司的竞争格局

赖诺普利市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 12 章：公司简介

顶级公司市占率分析
市场集中度
AbbVie Inc.

公司简介
公司收入
产品
最近的发展

Amneal Pharmaceutical Inc.

公司简介
公司收入
产品
最近的发展

AstraZeneca

公司简介
公司收入
产品
最近的发展

Apotex Inc.

公司简介
公司收入
产品
最近的发展

Aurobindo Pharma Ltd.

公司简介
公司收入
产品
最近的发展

Bausch Health Companies Inc.

公司简介
公司收入
产品
最近的发展

Cipla Limited

公司简介
公司收入
产品
最近的发展

Hikma Pharmaceutical PLC.

公司简介
公司收入
产品
最近的发展

Lupin Limited

公司简介
公司收入
产品
最近的发展

Merck & Co. Inc.

公司简介
公司收入
产品
最近的发展

Pfizer Inc.

公司简介
公司收入
产品
最近的发展

Sun Pharmaceutical Industries Limited

公司简介
公司收入
产品
最近的发展

Teva Pharmaceutical Industries Limited

公司简介
公司收入
产品
最近的发展

Vitaris Inc.

公司简介
公司收入
产品
最近的发展

Zydus Lifesciences Limited

公司简介
公司收入
产品
最近的发展

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112114732

The global demand for Lisinopril Market is presumed to reach the market size of nearly USD 3.35 Billion by 2032 from USD 2.09 Billion in 2023 with a CAGR of 5.36% under the study period 2024-2032.

Lisinopril is classified as an angiotensin-converting enzyme (ACE) inhibitor, primarily prescribed to treat high blood pressure (hypertension) and heart failure. Its mechanism involves relaxing blood vessels, which reduces blood pressure and improves blood flow. It is also prescribed to improve survival rates after heart attacks and to treat certain kidney conditions related to diabetes. Typically, it is taken orally, once a day, with or without food. Common side effects include dizziness, headaches, and cough. By effectively managing blood pressure, it helps lower the risk of strokes, heart attacks, and kidney problems.

MARKET DYNAMICS

The growing occurrence of hypertension and cardiovascular diseases is a significant driver, as lisinopril is widely prescribed to manage these conditions. With a growing global population and an increase in lifestyle-related health issues, the demand for effective antihypertensive medications continues to rise. Additionally, the drug's proven efficacy and safety profile make it a favored option among healthcare providers. The ongoing expansion of healthcare access in developing regions is another important factor. As more people gain access to medical care, the diagnosis and treatment of hypertension become more widespread, boosting the market growth. Moreover, the aging population contributes significantly to market growth, as older adults are more susceptible to hypertension and related cardiovascular conditions. Pharmaceutical companies are also investing in marketing and awareness campaigns to educate patients and healthcare professionals about the benefits of lisinopril, which helps to drive its adoption. Lastly, advancements in pharmaceutical manufacturing have enabled high-quality lisinopril production at more affordable prices, making it accessible to a broader patient base. However, the emergence of generic alternatives and potential side effects may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Lisinopril. The growth and trends of Lisinopril industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Lisinopril market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Dosage

Tablet
Liquid

By Dosage Strength

10 Mg
20 Mg
25 Mg

By Patient Age Group

Children
Adults

By Application

Hypertension
Heart Failure
Heart Attack
Diabetic Kidney Disease
Other

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Lisinopril market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Lisinopril market include AbbVie Inc., Amneal Pharmaceutical Inc., AstraZeneca, Apotex Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc., Cipla Limited, Hikma Pharmaceutical PLC., Lupin Limited, Merck & Co. Inc., Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Vitaris Inc., Zydus Lifesciences Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. LISINOPRIL - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Dosage
- 3.7.2 Market Attractiveness Analysis By Dosage Strength
- 3.7.3 Market Attractiveness Analysis By Patient Age Group
- 3.7.4 Market Attractiveness Analysis By Application
- 3.7.5 Market Attractiveness Analysis By Distribution Channel
- 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL LISINOPRIL MARKET ANALYSIS BY DOSAGE

5.1. Overview By Dosage
5.2. Historical and Forecast Data Analysis By Dosage
5.3. Tablet Historic and Forecast Sales By Regions
5.4. Liquid Historic and Forecast Sales By Regions

6. GLOBAL LISINOPRIL MARKET ANALYSIS BY DOSAGE STRENGTH

6.1. Overview By Dosage Strength
6.2. Historical and Forecast Data Analysis By Dosage Strength
6.3. 10 Mg Historic and Forecast Sales By Regions
6.4. 20 Mg Historic and Forecast Sales By Regions
6.5. 25 Mg Historic and Forecast Sales By Regions

7. GLOBAL LISINOPRIL MARKET ANALYSIS BY PATIENT AGE GROUP

7.1. Overview By Patient Age Group
7.2. Historical and Forecast Data Analysis By Patient Age Group
7.3. Children Historic and Forecast Sales By Regions
7.4. Adults Historic and Forecast Sales By Regions

8. GLOBAL LISINOPRIL MARKET ANALYSIS BY APPLICATION

8.1. Overview By Application
8.2. Historical and Forecast Data Analysis By Application
8.3. Hypertension Historic and Forecast Sales By Regions
8.4. Heart Failure Historic and Forecast Sales By Regions
8.5. Heart Attack Historic and Forecast Sales By Regions
8.6. Diabetic Kidney Disease Historic and Forecast Sales By Regions
8.7. Other Historic and Forecast Sales By Regions

9. GLOBAL LISINOPRIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL

9.1. Overview By Distribution Channel
9.2. Historical and Forecast Data Analysis By Distribution Channel
9.3. Hospital Pharmacy Historic and Forecast Sales By Regions
9.4. Retail Pharmacy Historic and Forecast Sales By Regions
9.5. Online Pharmacy Historic and Forecast Sales By Regions

10. GLOBAL LISINOPRIL MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1 Overview, Historic and Forecast Data Sales Analysis
- 10.3.2 North America By Segment Sales Analysis
- 10.3.3 North America By Country Sales Analysis
- 10.3.4 United States Sales Analysis
- 10.3.5 Canada Sales Analysis
- 10.3.6 Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1 Overview, Historic and Forecast Data Sales Analysis
- 10.4.2 Europe By Segment Sales Analysis
- 10.4.3 Europe By Country Sales Analysis
- 10.4.4 United Kingdom Sales Analysis
- 10.4.5 France Sales Analysis
- 10.4.6 Germany Sales Analysis
- 10.4.7 Italy Sales Analysis
- 10.4.8 Russia Sales Analysis
- 10.4.9 Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1 Overview, Historic and Forecast Data Sales Analysis
- 10.5.2 Asia Pacific By Segment Sales Analysis
- 10.5.3 Asia Pacific By Country Sales Analysis
- 10.5.4 China Sales Analysis
- 10.5.5 India Sales Analysis
- 10.5.6 Japan Sales Analysis
- 10.5.7 South Korea Sales Analysis
- 10.5.8 Australia Sales Analysis
- 10.5.9 South East Asia Sales Analysis
- 10.5.10 Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1 Overview, Historic and Forecast Data Sales Analysis
- 10.6.2 Latin America By Segment Sales Analysis
- 10.6.3 Latin America By Country Sales Analysis
- 10.6.4 Brazil Sales Analysis
- 10.6.5 Argentina Sales Analysis
- 10.6.6 Peru Sales Analysis
- 10.6.7 Chile Sales Analysis
- 10.6.8 Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1 Overview, Historic and Forecast Data Sales Analysis
- 10.7.2 Middle East & Africa By Segment Sales Analysis
- 10.7.3 Middle East & Africa By Country Sales Analysis
- 10.7.4 Saudi Arabia Sales Analysis
- 10.7.5 UAE Sales Analysis
- 10.7.6 Israel Sales Analysis
- 10.7.7 South Africa Sales Analysis
- 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE LISINOPRIL COMPANIES

11.1. Lisinopril Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12. COMPANY PROFILES OF LISINOPRIL INDUSTRY

12.1. Top Companies Market Share Analysis
12.2. Market Concentration Rate
12.3. AbbVie Inc.
- 12.3.1 Company Overview
- 12.3.2 Company Revenue
- 12.3.3 Products
- 12.3.4 Recent Developments
12.4. Amneal Pharmaceutical Inc.
- 12.4.1 Company Overview
- 12.4.2 Company Revenue
- 12.4.3 Products
- 12.4.4 Recent Developments
12.5. AstraZeneca
- 12.5.1 Company Overview
- 12.5.2 Company Revenue
- 12.5.3 Products
- 12.5.4 Recent Developments
12.6. Apotex Inc.
- 12.6.1 Company Overview
- 12.6.2 Company Revenue
- 12.6.3 Products
- 12.6.4 Recent Developments
12.7. Aurobindo Pharma Ltd.
- 12.7.1 Company Overview
- 12.7.2 Company Revenue
- 12.7.3 Products
- 12.7.4 Recent Developments
12.8. Bausch Health Companies Inc.
- 12.8.1 Company Overview
- 12.8.2 Company Revenue
- 12.8.3 Products
- 12.8.4 Recent Developments
12.9. Cipla Limited
- 12.9.1 Company Overview
- 12.9.2 Company Revenue
- 12.9.3 Products
- 12.9.4 Recent Developments
12.10. Hikma Pharmaceutical PLC.
- 12.10.1 Company Overview
- 12.10.2 Company Revenue
- 12.10.3 Products
- 12.10.4 Recent Developments
12.11. Lupin Limited
- 12.11.1 Company Overview
- 12.11.2 Company Revenue
- 12.11.3 Products
- 12.11.4 Recent Developments
12.12. Merck & Co. Inc.
- 12.12.1 Company Overview
- 12.12.2 Company Revenue
- 12.12.3 Products
- 12.12.4 Recent Developments
12.13. Pfizer Inc.
- 12.13.1 Company Overview
- 12.13.2 Company Revenue
- 12.13.3 Products
- 12.13.4 Recent Developments
12.14. Sun Pharmaceutical Industries Limited
- 12.14.1 Company Overview
- 12.14.2 Company Revenue
- 12.14.3 Products
- 12.14.4 Recent Developments
12.15. Teva Pharmaceutical Industries Limited
- 12.15.1 Company Overview
- 12.15.2 Company Revenue
- 12.15.3 Products
- 12.15.4 Recent Developments
12.16. Vitaris Inc.
- 12.16.1 Company Overview
- 12.16.2 Company Revenue
- 12.16.3 Products
- 12.16.4 Recent Developments
12.17. Zydus Lifesciences Limited
- 12.17.1 Company Overview
- 12.17.2 Company Revenue
- 12.17.3 Products
- 12.17.4 Recent Developments